Prevacus, Inc., a 2012 spin-out from Florida State University, has entered into an agreement with The Institute for the Commercialization of Public Research for funding to support clinical development of Prevasol nasal spray.
According to the company, Prevasol “utilizes Neurosteroids to improve behavioral outcomes of brain injury (working memory, sensory perception and anxiety levels) as well as enhance pro-survival molecular mechanisms after TBI (edema, apoptosis, inflammation, anti-oxidant defense, glial-immune cell infiltration).” The product is being developed for both prophylactic and post-injury use.
The Institute is a non-profit that provides funding for licensing and commercialization of technology developed at Florida universities and private research organizations.
Prevacus President Jake Van Landingham commented, “This funding comes at a critical time in our development. Paired with the private funding we’ve raised as a result of support from the Institute, Prevacus will be able to complete preclinical proof of concept studies, develop a drug safety profile and enter into large animal toxicology studies. All important activities will be completed for entry into Phase 1/2 clinical trials in the coming year.”
Read the Institute for the Commercialization of Public Research press release.
